Paion AG is a Germany-based biopharmaceutical company. The Company's main product is remimazolam, an intravenous ultra-short-acting benzodiazepine sedative and anesthetic. In the human body, remimazolam is metabolized to an inactive metabolite by tissue esterase and not metabolized by cytochrome-dependent hepatic pathways. In addition to that, remimazolam, which is in Phase III clinical development, can be reversed with flumazenil to terminate sedation and anesthesia, if necessary. The product can be used for general anesthesia in Europe and procedural sedation in the United States. The Company operates sites in Aachen, Germany, Cambridge, the United Kingdom, and New Jersey, the United States.

• Revenue in EUR (TTM)--
• Net income in EUR--
• Incorporated2004
• Employees64.00

• Location
  Paion AGHeussstrasse 25AACHEN 52078GermanyDEU
• Phone+49 24144530
• Fax+49 2 414453100
• Websitehttps://www.paion.com/